Matching articles for "Duavee"
Issue 1748 · February 16, 2026 Free
In Brief: Label Changes for Menopausal Hormone Therapy Products

The FDA has requested the removal of some boxed warnings from the labels of vaginal and systemic menopausal hormone therapy (MHT) products. The warnings were initially added in 2003 based on the results of two…

Med Lett Drugs Ther. 2026 Feb 16; 68(1748):30-1 doi:10.58347/tml.2026.1748d
The FDA has requested the removal of some boxed warnings from the labels of vaginal and systemic menopausal hormone therapy (MHT) products. The warnings were initially added in 2003 based on the results of two placebo-controlled Women's Health Initiative (WHI) trials evaluating the use of systemic hormones for primary prevention of coronary heart disease (CHD) in postmenopausal women 50-79 years old.
Issue 1744 · December 22, 2025
Elinzanetant (Lynkuet) for Menopausal Vasomotor Symptoms

Elinzanetant ( Lynkuet – Bayer), a first-in-class neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due…

Med Lett Drugs Ther. 2025 Dec 22; 67(1744):203-6 doi:10.58347/tml.2025.1744b
Elinzanetant ( Lynkuet – Bayer), a first-in-class neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. Fezolinetant (Veozah) , an NK3 receptor antagonist, was approved for the same indication in 2023.
Issue 1706 · July 8, 2024
Drugs for Postmenopausal Osteoporosis

Pharmacologic treatment is recommended for postmenopausal women who have bone density T-scores (standard deviations from normal mean values in the spine, femoral neck, total hip, or distal radius) of -2.5 or…

Med Lett Drugs Ther. 2024 Jul 8; 66(1706):105-12 doi:10.58347/tml.2024.1706a
Pharmacologic treatment is recommended for postmenopausal women who have bone density T-scores (standard deviations from normal mean values in the spine, femoral neck, total hip, or distal radius) of -2.5 or below, T-scores between -1.0 and -2.5 with a history of fragility (low-trauma) fracture of the hip or spine, or T-scores between -1.0 and -2.5 with a FRAX 10-year probability of ≥3% for hip fracture or ≥20% for major osteoporotic fracture.
Issue 1706 · July 8, 2024
Comparison Table: Some Drugs for Postmenopausal Osteoporosis (online only)

View the Comparison Table: Some Drugs for Postmenopausal Osteoporosis

Med Lett Drugs Ther. 2024 Jul 8; 66(1706):e112-4 doi:10.58347/tml.2024.1706b
View the Comparison Table: Some Drugs for Postmenopausal Osteoporosis
Issue 1697 · March 4, 2024
Drugs for Menopausal Symptoms

The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent…

Med Lett Drugs Ther. 2024 Mar 4; 66(1697):33-8 doi:10.58347/tml.2024.1697a
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Issue 1679 · June 26, 2023
Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms

Fezolinetant ( Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is…

Med Lett Drugs Ther. 2023 Jun 26; 65(1679):97-9 doi:10.58347/tml.2023.1679a
Fezolinetant ( Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is the second nonhormonal treatment to be approved in the US for this indication; a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate (Brisdelle) was approved in 2013.
Issue 1604 · August 10, 2020
Drugs for Menopausal Symptoms

The primary symptoms of menopause are genitourinary (genitourinary syndrome of menopause; GSM) and vasomotor (VMS). Vulvovaginal atrophy can cause vaginal burning, irritation and dryness, dyspareunia, and…

Med Lett Drugs Ther. 2020 Aug 10; 62(1604):124-8
The primary symptoms of menopause are genitourinary (genitourinary syndrome of menopause; GSM) and vasomotor (VMS). Vulvovaginal atrophy can cause vaginal burning, irritation and dryness, dyspareunia, and dysuria, and increase the risk of urinary tract infections. Vasomotor symptoms ("hot flashes") cause daytime discomfort and night sweats that may disrupt sleep. Hormone therapy is the most effective treatment for both genitourinary and vasomotor symptoms.
Issue 1602 · July 13, 2020
Drugs for Postmenopausal Osteoporosis

US guidelines recommend pharmacologic therapy for postmenopausal women with a bone density T-score (standard deviation from normal mean values in healthy young women) of -2.5 or below in the lumbar spine,…

Med Lett Drugs Ther. 2020 Jul 13; 62(1602):105-12
US guidelines recommend pharmacologic therapy for postmenopausal women with a bone density T-score (standard deviation from normal mean values in healthy young women) of -2.5 or below in the lumbar spine, femoral neck, total hip, or distal radius, a T-score between -1.0 and -2.5 and a history of fragility (low-trauma) fracture of the hip or spine, or a T-score between -1.0 and -2.5 and a FRAX 10-year probability of ≥3% for hip fracture or ≥20% for major osteoporotic fracture (hip, clinical spine, humerus, distal radius).
Issue 1602 · July 13, 2020
Comparison Table: Some Drugs for Postmenopausal Osteoporosis (online only)

View the Comparison Table: Some Drugs for Postmenopausal Osteoporosis

Med Lett Drugs Ther. 2020 Jul 13; 62(1602):e112-4
View the Comparison Table: Some Drugs for Postmenopausal Osteoporosis
Issue 1575 · July 1, 2019
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an…

Med Lett Drugs Ther. 2019 Jul 1; 61(1575):99-101
The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an intact uterus. The manufacturer is marketing Bijuva as "the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule".
Issue 1536 · December 18, 2017
Drugs for Postmenopausal Osteoporosis

Diagnosis of osteoporosis is based on the results of bone mineral density (BMD) testing or by the occurrence of a fragility fracture. Bone densitometry results are generally reported in terms of standard…

Med Lett Drugs Ther. 2017 Dec 18; 59(1536):203-10
Diagnosis of osteoporosis is based on the results of bone mineral density (BMD) testing or by the occurrence of a fragility fracture. Bone densitometry results are generally reported in terms of standard deviations (SD) from the mean value for young adults (T-score). The World Health Organization (WHO) defines osteoporosis in women as a T-score of -2.5 or below in the spine, femoral neck, or total hip. A computerized model (FRAX) is available that estimates the 10-year probability of a hip fracture or other major osteoporotic fracture based on clinical risk factors and BMD at the femoral neck.
Issue 1523 · June 19, 2017
Comparison Table: Drugs for Postmenopausal Osteoporosis (online only)

View the Comparison Table: Drugs for Postmenopausal Osteoporosis

Med Lett Drugs Ther. 2017 Jun 19; 59(1523):e104-6
View the Comparison Table: Drugs for Postmenopausal Osteoporosis
Issue 1507 · November 7, 2016
Drugs for Menopausal Symptoms

The primary symptoms of menopause are genitourinary and vasomotor. A thin, dry vaginal lining and thin urethral mucosa can cause vaginal and vulvar burning and irritation, pain during intercourse, and an…

Med Lett Drugs Ther. 2016 Nov 7; 58(1507):142-5
The primary symptoms of menopause are genitourinary and vasomotor. A thin, dry vaginal lining and thin urethral mucosa can cause vaginal and vulvar burning and irritation, pain during intercourse, and an increased risk of urinary tract infections. Vasomotor symptoms ("hot flashes") cause daytime discomfort and night sweats that may disrupt sleep.
Issue 1452 · September 29, 2014
Drugs for Postmenopausal Osteoporosis

US guidelines for the treatment of osteoporosis have been published. The diagnosis of osteoporosis has traditionally been established by the occurrence of fragility fractures or by bone densitometry, which is…

Med Lett Drugs Ther. 2014 Sep 29; 56(1452):91-6
US guidelines for the treatment of osteoporosis have been published. The diagnosis of osteoporosis has traditionally been established by the occurrence of fragility fractures or by bone densitometry, which is generally reported in terms of standard deviations (SD) from mean values in young adults (T-score). The World Health Organization (WHO) has defined normal bone mineral density (BMD) for women as a value within one SD of the young adult mean. Values 2.5 SD or more below the mean (T-score -2.5 or below) at the spine, femoral neck, or total hip are defined as osteoporosis. The WHO has developed a computerized model (FRAX) that predicts the 10-year probability of a hip fracture or other major osteoporotic fracture based on clinical risk factors and BMD at the femoral neck.
Issue 1441 · April 28, 2014
Conjugated Estrogens/Bazedoxifene (Duavee) for Menopausal Symptoms and Prevention of Osteoporosis

The FDA has approved Duavee (Pfizer), a fixed-dose combination of conjugated estrogens and the new selective estrogen receptor modulator (SERM) bazedoxifene, for treatment of moderate to severe vasomotor…

Med Lett Drugs Ther. 2014 Apr 28; 56(1441):33-4
The FDA has approved Duavee (Pfizer), a fixed-dose combination of conjugated estrogens and the new selective estrogen receptor modulator (SERM) bazedoxifene, for treatment of moderate to severe vasomotor symptoms and for prevention of osteoporosis in postmenopausal women with an intact uterus. Bazedoxifene is an estrogen agonist/antagonist with estrogen-like effects on bone and antiestrogen effects on the uterus. It is the second SERM to be approved for prevention of osteoporosis; raloxifene ( Evista , and generics) has been available as a single agent for this indication since 1997.